Company Yuhan Corporation

A000100

KR7000100008

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Yuhan Corporation

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 29/04/2024 BST			5-day change	1st Jan Change
72,400 ^KRW	-0.69%		+1.12%	+5.23%

04-24	Korean Sugar Imports Plunge 14% as Diabetes Cases Surge	MT
03-07	Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.

Number of employees: 1,999

KRW in Million	2022	Weight	2023	Weight	Delta
Pharmaceuticals, Chemicals, Industrial Drugs, Veterinary Drugs, Household Goods, Etc. 100.0 %	1,775,847	100.0 %	1,858,984	100.0 %	+4.68%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea, United States, Hong Kong, Australia, and Uzbekistan 100.0 %	1,775,847	100.0 %	1,858,984	100.0 %	+4.68%

Managers	Title	Age	Since
Wuk-Jae Cho CEO	Chief Executive Officer	69	30/04/87
Jeong-Hui Lee CHM	Chairman	72	30/04/78
Byeong-Man Lee BRD	Director/Board Member	66	-
Tae-Jin Yoon PRN	Corporate Officer/Principal	54	31/07/15
Byung-Chul Lee AUD	Comptroller/Controller/Auditor	60	31/03/92
Young-Rae Lee PRN	Corporate Officer/Principal	63	28/02/87

Members of the board	Title	Age	Since
Jeong-Hui Lee CHM	Chairman	72	30/04/78
Wuk-Jae Cho CEO	Chief Executive Officer	69	30/04/87
Byeong-Man Lee BRD	Director/Board Member	66	-
Yeong-Jae Shin BRD	Director/Board Member	57	18/03/21
Young-Rae Lee PRN	Corporate Officer/Principal	63	28/02/87
Dong-Jin Park BRD	Director/Board Member	59	-
Seong-Gil Ji BRD	Director/Board Member	61	19/03/20
Jun-Chul Kim BRD	Director/Board Member	59	18/03/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	80,209,071	54,771,420 ( 68.29 %)	6,697,804 ( 8.350 %)	67.30 %
Stock B	0	1,180,940	0	32,600 ( 2.761 %)

Name	Equities	%	Valuation
Yuhan Foundation 15.82 %	12,689,282	15.82 %	723 M ₩
National Pension Service of Korea 9.827 %	7,881,911	9.827 %	449 M ₩
YUHAN CORPORATION 8.350 %	6,697,798	8.350 %	382 M ₩
Mirae Asset Global Investments Co., Ltd. 0.2748 %	220,406	0.2748 %	13 M ₩
Sjunde AP-fonden 0.2151 %	172,542	0.2151 %	10 M ₩
State Street Global Advisors Ltd. 0.1398 %	112,157	0.1398 %	6 M ₩
KB Asset Management Co., Ltd. 0.1297 %	104,042	0.1297 %	6 M ₩
DWS Investment SA Luxembourg (Investment Management) 0.0923 %	74,019	0.0923 %	4 M ₩
Kyobo AXA Investment Managers Co., Ltd. 0.0707 %	56,704	0.0707 %	3 M ₩
Jung-Hee Lee 0.0691 %	55,400	0.0691 %	3 M ₩

Name	Equities	%	Valuation
DWS Investment SA Luxembourg (Investment Management) 3.501 %	41,350	3.501 %	2 M ₩
YUHAN CORPORATION 2.761 %	32,600	2.761 %	2 M ₩
Yuhan Foundation 0.0423 %	500	0.0423 %	24 104 ₩

Name	Equities	%	Valuation
YUHAN CORPORATION 8.35%	6,697,798	8.35%	381,594,114 $
APRILBIO CO.,LTD. 9.97%	2,155,750	9.97%	26,213,273 $
GI INNOVATION, INC. 3.55%	1,566,060	3.55%	15,366,870 $
PROGEN CO., LTD. 18.13%	2,095,002	18.13%	10,473,062 $
THERAGEN ETEX CO.,LTD. 7.71%	2,503,128	7.71%	8,134,590 $
GENEXINE, INC. 1.18%	491,570	1.18%	3,176,722 $
PROCESSA PHARMACEUTICALS, INC. 3.66%	62,500	3.66%	147,813 $

Yuhan Corp.

Yuhan Building 74 Noryangjin-ro

06927, Seoul

http://www.yuhan.co.kr

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

72,400 KRW

Average target price

85,674 KRW

Spread / Average Target

+18.33%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
YUHAN CORPORATION	+5.23%	3.9B
KYOWA KIRIN CO. LTD.	+12.55%	9.06B
SK BIOPHARMACEUTICALS CO., LTD.	-12.75%	4.96B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+42.38%	4.47B
INDIVIOR PLC	+20.59%	2.41B
BETTA PHARMACEUTICALS CO., LTD.	-19.05%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-28.72%	2.23B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+11.13%	2.02B
SUPERNUS PHARMACEUTICALS, INC.	+3.94%	1.65B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals